Relative quantification of tumor associated antigens MAGE-1 and MAGE-A3 in Multiple myeloma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14310%2F06%3A00017612" target="_blank" >RIV/00216224:14310/06:00017612 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Relative quantification of tumor associated antigens MAGE-1 and MAGE-A3 in Multiple myeloma
Original language description
The aim of this study was to evaluate the posibility of using these genes as molecular markers of the progression MGUS to MM and the early relapse of the MM. Due to rare extramedullary location of malignant plasma cells we tried to undercover if expression is detecable in PB simultaneously with expression in the BM. Total of 151 samples from BM were evaluated: 83 samples from advanced myeloma, 12 samples of patients with early stage of MM who did not required treatment (smoldering MM 4x, stage IA 8x), 41 samples of MGUS patiens and 15 samples of normal healthy donors served as control group. In 15 advanced myeloma patients we simultaneously assessed BM sample and PB sample. Total RNA was evaluated by RT-PCR and then by real-time PCR using FRET probes.For relative quantification we used G6PDH housekeeping gene as external standard. As positive control we used myeloma cell line U266.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/LC06027" target="_blank" >LC06027: University Research Centre - Czech Myeloma Group</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2006
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů